Robert Steyer

Special to TheStreet.com

Robert Steyer, who joined TheStreet.com in July 2003, has written about the business of science, medicine and health care for the St. Louis Post-Dispatch and the Newark Star-Ledger. He also has been a reporter for Fortune, an editor at CFO Magazine and an assistant business editor at the Tampa Tribune.

He has a B.A. in government from Oberlin College and an M.B.A. from New York University.

Robert Steyer
By This Author:
« Back
Page 1 of 148
Article

Are Fund Managers Better Than Their Funds?

By Robert Steyer

For investors still cringing at their IRAs, 401(k)s or taxable mutual funds and exchange-traded funds, are you ready to take a chance on the companies that have brought you so many unhappy returns?

04:51PM 04/20/09

Article

Can Regional Brokers Keep Outperforming?

By Robert Steyer

The regionals may not have as much recognition as the mammoth securities firms, but they won't be receiving as many unwanted headlines either.

10:49AM 02/16/09

Article

Wyeth Deal's Big, but Pfizer Still Needs a Blockbuster

By Robert Steyer

If Pfizer's looking for the next Lipitor, it probably hasn't found it with the acquisition of Wyeth.

04:43PM 01/26/09

Article

Cosmetic Surgery Stocks Keep Stiff Upper Lip

By Robert Steyer

Allergan, Mentor and Medicis have struggled in the past year, but if the economy improves, share prices could, too.

05:05PM 10/28/08

Article

For Abbott, Diversity Remains Paramount

By Robert Steyer

When it comes to investing in big pharmaceutical stocks, it's hard to top this company, especially as its peers continue to suffer.

01:06PM 08/21/08

Article

Legal Questions Still Dogging Wyeth

By Robert Steyer

The company continues to wrestle with the dilemma surrounding the drugs Premarin, Prempro and Premphase. Plaintiffs' lawyers have filed approximately 5,400 lawsuits.

12:37PM 07/21/08

Article

Baxter International Hiding in Plain Sight

By Robert Steyer

In the past five years, its stock has more than tripled, easily outperforming the S&P 500 and the Amex Index of large drug stocks. Is anyone paying attention?

06:59AM 07/01/08

Article

Generic-Drug Stocks Still Under the Weather

By Robert Steyer

Shares of most major generic-drugmakers have traded below the S&P 500 for the 12 months ended May 23, and that index was off nearly 10%.

01:40PM 06/05/08

Article

Need Defense? Think Medical Supplies

By Robert Steyer

Companies such as C.R. Bard and Becton Dickinson might not be the most glamorous names, but their slow and steady performances may win the race.

06:44AM 04/11/08

Article

The Real Winners of Drug Experimentation

By Robert Steyer

The companies that supply the tools needed for pharma research and development often profit no matter the success of a drug trial.

06:59AM 04/03/08

« Back
Page 1 of 148
Dow Jones S&P 500 NASDAQ 10-Year Note
10,450.95 1,106.24 2,176.01 33.64
Oil *
77.66
UP
132.79
UP
14.86
UP
29.97
UP
0.08
10 Yr
3.36%
SPDR Gold
114.29
+1.29%
+1.36%
+1.40%
+0.24%
Data delayed 20 minutes

Brokerage Partners